Curtis Wright IV

FDA Approval of OxyContin Reveals Systemic Regulatory Capture by Purdue Pharma

1995-12-12 00:00:00 +0000 UTC | Importance: 9/10

In a landmark case of regulatory capture, Dr. Curtis Wright IV, leading the FDA’s Division of Anesthetic, Critical Care, and Addiction Drug Products, approved OxyContin with controversial language that misrepresented the drug’s addictive potential. Wright held private meetings with …

Curtis Wright IV Purdue Pharma Food and Drug Administration Division of Anesthetic, Critical Care, and Addiction Drug Products Department of Justice regulatory-capture pharmaceutical-industry opioid-crisis fda-corruption public-health